Most Read Articles
Yesterday
Administering intranasal desmopressin to patients with renal dysfunction not requiring haemodialysis reduces bleeding complications during renal biopsies, especially minor complications such as perinephric haematomas, a study has found. However, it may increase the risk of incident hyponatraemia.
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
3 days ago
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 5 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.

Ustekinumab effective for IBD with concomitant psoriasis, psoriatic arthritis

03 Jul 2019
Crohn’s is not the end of the world, as Kathleen Baker’s silver medal proves

Ustekinumab, delivered subcutaneously, is effective for patients with inflammatory bowel disease (IBD) receiving concomitant treatment for dermatological or rheumatological conditions, a recent study has found.

Researchers conducted a multicentre, retrospective analysis of 70 IBD patients (median age, 41.75 years; 45 percent female; 91.4 percent Crohn’s disease) who were initiated on ustekinumab for concomitant active psoriasis or psoriatic arthritis. The primary study endpoint was overall persistence of ustekinumab, defined as therapy maintenance due to sustained clinical benefit.

The median time on ustekinumab was 10.7 months. Twelve patients (17.1 percent) withdrew from the medication, all of whom had CD. Median time to withdrawal was 7.4 months. Half of the withdrawals were due to the lack of benefit for the skin or joint disease, four due to lack of benefit for IBD, and two due to adverse events.

At baseline, 56 patients had active disease. At the last follow-up after ustekinumab treatment, majority of these participants (60.7 percent; n=34) were in clinical remission. The cumulative probabilities of achieving remission at 6 and 9 months were 84.7 percent and 63.9 percent, respectively.

Disaggregating according to comorbid conditions did not meaningfully change the results. Ustekinumab induced clinical remission in majority of patients with either psoriasis (82.2 percent; 37 of 45) or psoriatic arthritis (60 percent; 15 of 25).

Ustekinumab likewise had a favourable safety profile. Only 10 cases of adverse events were reported in nine participants. Three adverse events needed emergency care: acute intestinal obstruction, dehydration due to acute gastroenteritis and acute renal colic.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Administering intranasal desmopressin to patients with renal dysfunction not requiring haemodialysis reduces bleeding complications during renal biopsies, especially minor complications such as perinephric haematomas, a study has found. However, it may increase the risk of incident hyponatraemia.
Pearl Toh, 10 Oct 2019
Adding a LAMA* to the double combination therapy of ICS** plus LABA*** in a single inhaler improves lung function and reduces exacerbations in patients whose asthma is inadequately controlled with the combination treatment, according to the TRIMARAN and TRIGGER# studies presented at ERS 2019.
3 days ago
Environmental quality and exposure to pollution may play a small part in the development of metabolic diseases, such as diabetes, a new study has found.
Tristan Manalac, 5 days ago
Sleep deprivation impairs adolescents’ long-term retention of classroom material, according to a recent Singapore study.